Half-year report · Q2
4574.TEDINET S100U6M9
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.9bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Operating income | ¥482m | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Operating income | −¥396m | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Ordinary income | ¥528m | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥510m | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥724m | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥492m | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥3.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥514m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Net income | −¥514m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Total assets | ¥13.4bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥13.2bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥15.6bn | at 2023-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.3bn | at 2024-06-30 | Cons. | Liabilities |
| Total liabilities | ¥6.5bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.1bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥9.2bn | at 2023-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.2bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.5bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.2bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥256m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥307m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥126m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥135m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥707m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥562m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥827m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥15.24 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-76.25 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.36 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 60.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.0% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | segment profit | 2024-01-01 → 2024-06-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥401m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥195m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-06-30 | ¥884m |
| Otherother segments | revenue | 2023-01-01 → 2023-06-30 | ¥2m |
| Otherother segments | revenue external | 2023-01-01 → 2023-06-30 | ¥2m |
| Otherother segments | segment profit | 2023-01-01 → 2023-06-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥492m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥370m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥370m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥407m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥2.1bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥2.1bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥514m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-06-30 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-06-30 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-06-30 | ¥95m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 518
| Item | Context | Value | Unit |
|---|---|---|---|
| Advertising expenses sga | Prior1YTDDuration | 92000000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 58000000 | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 386000000 | JPY |
| Payroll and allowances sga | CurrentYTDDuration | 390000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 33000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 29000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 22000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 27000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2115000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 370000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2488000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 2488000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2115000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 370000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2488000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 2488000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 514000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | -407000000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | -11000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 95000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -492000000 | JPY |
| Operating income | Prior1YTDDuration | -396000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2654000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 203000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2860000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 2860000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 2654000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | 203000000 | JPY |
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2860000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 2860000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |